# A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma

> **NCT05139225** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** TTI-622
- **DRUG:** Daratumumab Hyaluronidase-fihj

## Key facts

- **NCT ID:** NCT05139225
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-28
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05139225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05139225, "A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05139225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*